Trial · NCT04687072
Results by group166
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 166
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 | Efgartigimod PH20 SC | 13.7 | percentage of participants | ||
| Percentage of Participants With Chronic Immune Thrombocytopenia (ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 | Placebo PH20 SC | 16.2 | percentage of participants | ||
| Extent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population | Efgartigimod PH20 SC | 0.5 | Full Range 0 to 24 | weeks | |
| Extent of Disease Control Over the 24-Week Treatment Period in the Chronic ITP Population | Placebo PH20 SC | 0.0 | Full Range 0 to 23 | weeks | |
| Percentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 | Efgartigimod PH20 SC | 16.1 | percentage of participants | ||
| Percentage of Participants in the Overall Population (Chronic and Persistent ITP) With a Sustained Platelet Count Response Between Weeks 19 and 24 | Placebo PH20 SC | 15.7 | percentage of participants | ||
| Percentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 24 | Efgartigimod PH20 SC | 12.4 | percentage of participants | ||
| Percentage of Participants in the Overall Population With Sustained Platelet Count Response Between Weeks 17 and 24 | Placebo PH20 SC | 14.3 | percentage of participants | ||
| Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period | Efgartigimod PH20 SC | 29.9 | percentage of participants | ||
| Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time During the 24-week Treatment Period | Placebo PH20 SC | 25.7 | percentage of participants | ||
| Extent of Disease Control Until Week 12 in the Overall Population | Efgartigimod PH20 SC | 0.00 | Full Range 0.00 to 12.00 | weeks | |
| Extent of Disease Control Until Week 12 in the Overall Population | Placebo PH20 SC | 0.00 | Full Range 0.00 to 11.00 | weeks | |
| Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 12 | Efgartigimod PH20 SC | 18.2 | percentage of participants | ||
| Percentage of Participants in the Overall Population Achieving Overall Platelet Count Response at Any Time Until Week 12 | Placebo PH20 SC | 15.7 | percentage of participants | ||
| Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population | Efgartigimod PH20 SC | Week 1 | 13.84 | Standard Deviation 41.150 | platelets x10^9/L |
| Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population | Placebo PH20 SC | Week 1 | 8.82 | Standard Deviation 34.355 | platelets x10^9/L |
| Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population | Efgartigimod PH20 SC | Week 2 | 16.62 | Standard Deviation 49.408 | platelets x10^9/L |
| Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population | Placebo PH20 SC | Week 2 | 23.54 | Standard Deviation 85.005 | platelets x10^9/L |
| Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population | Efgartigimod PH20 SC | Week 3 | 17.07 | Standard Deviation 39.855 | platelets x10^9/L |
| Mean Change From Baseline in Platelet Count at Each Visit in the Overall Population | Placebo PH20 SC | Week 3 | 19.22 | Standard Deviation 71.947 | platelets x10^9/L |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04687072/results